Antisoma adds more positive data for AS1404

Antisoma is adding more positive data for its closely-watched lung cancer therapy AS1404. Lung cancer patients taking the treatment with chemotherapy experienced greater delays for tumor progression than had been reported earlier. In the trial, tumor response rates hit 31 percent with AS1404 as compared to 22 percent for chemo alone. Antisoma has been in talks to sign a licensing partner for the therapy, which is headed for Phase III next year. Antisoma says AS1404 can compete with Avastin. If they're right, it would be a blockbuster.

- here's the AFX report on the data

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.